Melanotan I
Melanotan I. α-MSH analog approved for erythropoietic protoporphyria to promote photoprotective pigmentation.
How it works. Selective MC1R agonism increases melanocyte eumelanin production, providing endogenous photoprotection.
What the research supports. 2 graded claims. Strongest: Disease-modifying option in EPP (preclinical).
Hormonal impact. Effects on Melanocortin signaling (MC1R), Other melanocortin receptors.
Side effects and interactions. 0 medication interactions listed. Serious: Need for melanocytic surveillance with chronic use.
Stacking. Pairs well with Standard photoprotection (clothing, sunscreen). Avoid combining with History of melanoma.
Common forms. Available as Subcutaneous implant.
Community. Experiences from people who have tried Melanotan I. Anecdotes are not medical advice.
Melanotan I. α-MSH analog approved for erythropoietic protoporphyria to promote photoprotective pigmentation.
What it is
Melanotan I (afamelanotide) is a synthetic α-MSH analog approved to reduce phototoxicity in erythropoietic protoporphyria via increased eumelanin production.
Also called
How it works
Selective MC1R agonism increases melanocyte eumelanin production, providing endogenous photoprotection.
Pathways
- MC1R agonism
- Eumelanin synthesis
- Reduced UV-driven oxidative stress
Effects
- ↑Eumelanin-mediated photoprotection increases
- ↓Phototoxic events in EPP decreases
What the research supports
Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.
Hormonal impact
Side effects & interactions
Common side effects
- Headache
- Nausea
- Injection-site reactions
Serious
- Need for melanocytic surveillance with chronic use
No notable medication interactions listed.
Check any supplement–medication combination with your pharmacist before starting.
Combines with
Pairs well
- Standard photoprotection (clothing, sunscreen)Combined behavioral and pharmacologic protection.
Avoid combining
- History of melanomaRisk-benefit unfavorable.
Common forms
- Subcutaneous implant
Discussion
Loading discussion…